Has Andrew Hsu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $456,013 in general payments to Andrew Hsu, MD across 431 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Hsu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Hsu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Hsu, MD

Foot and Ankle Surgery · Orange, CANPI 1497983761

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $355,329 of the $456,013 with a category attached, or 77.9%. Arthrex accounts for 99.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $153,939 and has fallen 65.7% since, to $52,826 in 2025. Among foot and ankle surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$456,013in general payments, 2019–2025

Across 431 payments — averaging $1058.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Arthrex$453K
Heron Therapeutics, Inc.$2K
Integra Lifesciences Corporation$293
Stryker$155
Janssen Scientific Affairs, LLC$96
Paragon 28, Inc.$77
plus $69 from 3 others

What the payments were for

Consulting fees$75,65417%
Speaking & faculty fees$355,32978%
Travel & lodging$18,2494%
Food & beverage$6,4881%
Other$2930%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Arthrex	422	$453,323
Heron Therapeutics, Inc.	1	$2,000
Integra Lifesciences Corporation	1	$293
Stryker	2	$155
Janssen Scientific Affairs, LLC	1	$96
Paragon 28, Inc.	1	$77
Abbott	1	$25
Medtronic	1	$25
Johnson & Johnson	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Zynrelef$2,000
DISTAL EXTREMITIES IMPLANTS MIDFOOT PLATES & SCREWS MIDFOOT FRACTURE$850
DISTAL EXTREMITIES IMPLANTS HINDFOOT & ANKLE ANKLE FRACTURE$425
DISTAL EXTREMITIES IMPLANTS HAND & WRIST MINI FRAGMENT$425
DISTAL EXTREMITIES IMPLANTS HINDFOOT & ANKLE ANKLE FUSION$425
DISTAL EXTREMITIES IMPLANTS HINDFOOT & ANKLE EXTERNAL FIXATION$425
MICROMATRIX$293
DISTAL EXTREMITIES IMPLANTS MIDFOOT PLATES & SCREWS MIDFOOT SCREWS$213
INFINITY$134
DISTAL EXTREMITIES IMPLANTS FRACTURE MANAGEMENT ANKLE FRACTURE$101

How this compares

$456,013 in reported general payments places this provider in the 95th percentile of 1,126 foot and ankle surgery providers in California.

See all foot and ankle surgery providers in California →

Medicare billing

Part B allowed, 2024

$263,123

Medicare patients

585

Services billed

3,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	86	$5,438
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	107	$3,875
Diclofenac Sodium	44	$1,697
Ciclopirox	42	$1,434
Clobetasol Propionate	24	$782
Terbinafine Hcl	42	$593
Econazole Nitrate	16	$498
Gabapentin	67	$484
Pregabalin	37	$432
Meloxicam	85	$330
Oxycodone Hcl	26	$277
Mupirocin	52	$206
Ibuprofen	27	$201

Paid to pharmacies, not to this prescriber.

Other foot and ankle surgery in Orange

Brandon HaghverdianOrange$84K
Eric GizaSacramento$3.6M
Thomas HarrisPasadena$3M
Thomas ChangSanta Rosa$2M
Michael CoughlinSan Francisco$1.6M
Vladimir ZeetserEncino$677K
Jason NowakRedding$526K
Candice BradyCamarillo$462K
Eric TanLos Angeles$447K
Joseph ParkBurbank$387K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →